BAX Share Price | Baxter International, Inc. Stock Analysis & Recommendation

Q: How big is Baxter International, Inc.?

Market Cap: As of Jun 18, Baxter International, Inc. has a market capitalization of 20,615.97 million, classifying it as a Large Cap company.Recent Quarterly Performance: For the latest four quarters, Baxter International, Inc. reported net sales of 11,889.00 million and a net profit of -674.00 million.Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 6,964.00 million and total assets of 25,782.00 million.

Q: What does Baxter International, Inc. do?

Overview:Baxter International, Inc. provides renal and hospital products within the Pharmaceuticals & Biotechnology industry and operates in the large-cap market segment.Financial Snapshot:Most recent Net Sales: 2,625 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 64 Million (Quarterly Results - Mar 2025) Market-cap: USD 20,615.97 Million (Large Cap)Key Metrics:P/E: 31.00 Dividend Yield: 1.97% Debt Equity: 1.10 Return on Equity: 9.41% Price to Book: 2.91 Contact Details:Address: 1 Baxter Pkwy, DEERFIELD IL: 60015-4625 Tel: 1 847 9482000 Website: https://www.baxter.com/

Q: Who are in the management team of Baxter International, Inc.?

As of March 2022, the management team of Baxter International, Inc. includes Mr. Jose Almeida, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Mr. Thomas Stallkamp as the Lead Independent Director, along with several Independent Directors: Mr. Thomas Chen, Mr. John Forsyth, Dr. James Gavin, and Mr. Peter Hellman.

Q: Is Baxter International, Inc. overvalued or undervalued?

As of 8 February 2024, Baxter International, Inc. has moved from a fair to a risky valuation grade. The company appears to be overvalued, as indicated by its P/E ratio of 31, which is significantly higher than its peer Align Technology, Inc. with a P/E of 20.46. Additionally, Baxter's EV to EBITDA ratio stands at 32.83, compared to Align's 11.41, further highlighting the disparity in valuation metrics. The Price to Book Value of 2.94 also suggests that the stock is trading at a premium relative to its book value.In terms of recent performance, Baxter has underperformed against the S&P 500, with a year-to-date return of -18.76% compared to the index's 12.22%. Over the past three years, Baxter's stock has declined by 59.28%, while the S&P 500 has gained 70.41%, reinforcing the notion that the stock is currently overvalued.

Q: Is Baxter International, Inc. technically bullish or bearish?

As of 14 July 2025, the technical trend for Baxter International, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with a strong indication from the weekly and monthly MACD, both showing bearish signals. The daily moving averages also confirm a bearish trend. Although the weekly RSI is bullish, it is overshadowed by the overall bearish indicators from Bollinger Bands and KST. The Dow Theory indicates a mildly bearish stance on the weekly timeframe. In terms of performance, Baxter has underperformed significantly compared to the S&P 500 across all multi-period returns, with a year-to-date return of -18.76% versus the S&P 500's 12.22%, and a one-year return of -39.83% compared to the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

13.19 M

Shareholding (Dec 2025)

FII

18.81%

Held by 347 FIIs

DII

23.54%

Held by 122 DIIs

Promoter

0.12%

How big is Baxter International, Inc.?

22-Jun-2025

As of Jun 18, Baxter International, Inc. has a market capitalization of $20.62 billion, with net sales of $11.89 billion and a net profit of -$674 million over the last four quarters.

View full answer

What does Baxter International, Inc. do?

22-Jun-2025

Baxter International, Inc. specializes in renal and hospital products within the Pharmaceuticals & Biotechnology industry, with a recent net sales of $2.625 billion and a market cap of approximately $20.62 billion. Key financial metrics include a P/E ratio of 31.00 and a dividend yield of 1.97%.

View full answer

Who are in the management team of Baxter International, Inc.?

22-Jun-2025

As of March 2022, Baxter International, Inc.'s management team includes Mr. Jose Almeida as Chairman, President, and CEO, and Mr. Thomas Stallkamp as Lead Independent Director, along with several Independent Directors.

View full answer

Is Baxter International, Inc. overvalued or undervalued?

20-Sep-2025

As of February 8, 2024, Baxter International, Inc. is considered overvalued with a P/E ratio of 31 compared to its peer Align Technology's 20.46, and has underperformed the S&P 500 with a year-to-date return of -18.76% and a three-year decline of 59.28%.

View full answer

Is Baxter International, Inc. technically bullish or bearish?

20-Sep-2025

As of July 14, 2025, Baxter International, Inc. is in a bearish trend, indicated by negative signals from MACD and moving averages, despite a bullish weekly RSI, and has significantly underperformed the S&P 500 with year-to-date and one-year returns of -18.76% and -39.83%, respectively.

View full answer

Compare Baxter International, Inc. with Similar Stocks

STERIS Plc (Ireland)ResMed, Inc.Align Technology, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Weak Long Term Fundamental Strength with a -17.50% CAGR growth in Operating Profits over the last 5 years

Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.86 times

The company has declared Negative results for the last 3 consecutive quarters

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 11,791 Million (Small Cap)

P/E

46.00

Industry P/E

Dividend Yield

1.56%

Debt Equity

1.23

Return on Equity

4.23%

Price to Book

1.92

Revenue and Profits:

Net Sales:

2,974 Million

(Quarterly Results - Dec 2025)

Net Profit:

-1,035 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-10.34%

6 Months

-28.45%

1 Year

-50.62%

2 Years

-58.95%

3 Years

-55.49%

4 Years

-78.37%

5 Years

-78.36%

Baxter International, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-0.75%

EBIT Growth (5y)

-17.62%

EBIT to Interest (avg)

5.83

Debt to EBITDA (avg)

3.86

Net Debt to Equity (avg)

1.10

Sales to Capital Employed (avg)

0.65

Tax Ratio

5.34%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

9.07%

ROE (avg)

13.65%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.92

EV to EBIT

28.10

EV to EBITDA

11.59

EV to Capital Employed

1.41

EV to Sales

1.72

PEG Ratio

Dividend Yield

1.56%

ROCE (Latest)

5.03%

ROE (Latest)

4.23%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 133 Schemes (57.31%)

Foreign Institutions

Held by 347 Foreign Institutions (18.81%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 8.03% vs -29.14% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -112.09% vs -768.49% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,974.00",
          "val2": "2,753.00",
          "chgp": "8.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "357.00",
          "val2": "419.00",
          "chgp": "-14.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "67.00",
          "val2": "98.00",
          "chgp": "-31.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-883.00",
          "val2": "-603.00",
          "chgp": "-46.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1,035.00",
          "val2": "-488.00",
          "chgp": "-112.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "39.30%",
          "val2": "63.20%",
          "chgp": "-2.39%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 5.72% vs 2.66% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -176.07% vs -280.11% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11,244.00",
          "val2": "10,636.00",
          "chgp": "5.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,674.00",
          "val2": "1,684.00",
          "chgp": "-0.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "284.00",
          "val2": "402.00",
          "chgp": "-29.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,170.00",
          "val2": "-711.00",
          "chgp": "-64.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-900.00",
          "val2": "-326.00",
          "chgp": "-176.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "61.60%",
          "val2": "64.60%",
          "chgp": "-0.30%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

2,974.00

2,753.00

8.03%

Operating Profit (PBDIT) excl Other Income

357.00

419.00

-14.80%

Interest

67.00

98.00

-31.63%

Exceptional Items

-883.00

-603.00

-46.43%

Consolidate Net Profit

-1,035.00

-488.00

-112.09%

Operating Profit Margin (Excl OI)

39.30%

63.20%

-2.39%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 8.03% vs -29.14% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -112.09% vs -768.49% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

11,244.00

10,636.00

5.72%

Operating Profit (PBDIT) excl Other Income

1,674.00

1,684.00

-0.59%

Interest

284.00

402.00

-29.35%

Exceptional Items

-1,170.00

-711.00

-64.56%

Consolidate Net Profit

-900.00

-326.00

-176.07%

Operating Profit Margin (Excl OI)

61.60%

64.60%

-0.30%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 5.72% vs 2.66% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -176.07% vs -280.11% in Dec 2024

All Annual Results

Company CV

About Baxter International, Inc.

Baxter International, Inc.

Pharmaceuticals & Biotechnology

Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.

Company Coordinates

Company Details

1 Baxter Pkwy , DEERFIELD IL : 60015-4625

Tel: 1 847 9482000

https://www.baxter.com/

Registrar Details